John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Dalgaard, Frederik, Haolin Xu, Roland A. Matsouaka, Andrea M. Russo, Anne B. Curtis, Peter Vibe Rasmussen, Martin H. Ruwald, et al. “Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation.” Journal of the American Heart Association 9, no. 23 (December 2020): e017024. https://doi.org/10.1161/jaha.120.017024.

PMID
33241750
Full Text

Alexander, John H., and Peter K. Smith. “Are We At Risk of Depriving Patients Lifesaving Cardiac Surgery?: Implications of the ISCHEMIA Trial for Coronary Artery Bypass Graft Surgery.” Circulation 142, no. 19 (November 10, 2020): 1797–98. https://doi.org/10.1161/CIRCULATIONAHA.120.050524.

PMID
33166217
Full Text

Gibson, C Michael, John J. P. Kastelein, Adam T. Phillips, Philip E. Aylward, Megan K. Yee, Michal Tendera, Stephen J. Nicholls, et al. “Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.” Am Heart J, October 13, 2020. https://doi.org/10.1016/j.ahj.2020.10.052.

PMID
33065120
Full Text

Lopes, Renato D., Amit N. Vora, and John H. Alexander. “Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention-Reply.” Jama Cardiol, October 7, 2020. https://doi.org/10.1001/jamacardio.2020.4759.

PMID
33026416
Full Text

Gaudino, Mario, John H. Alexander, Natalia Egorova, Paul Kurlansky, Andre Lamy, Faisal Bakaeen, Irbaz Hameed, et al. “Sex-related differences in outcomes after coronary artery bypass surgery-A patient-level pooled analysis of randomized controlled trials: rationale and study protocol.” J Card Surg 35, no. 10 (October 2020): 2754–58. https://doi.org/10.1111/jocs.14903.

PMID
32720394
Full Text

Jawitz, Oliver K., Morgan L. Cox, David Ranney, Judson B. Williams, Hillary Mulder, Mario F. L. Gaudino, Stephen Fremes, et al. “Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.” Am Heart J 228 (October 2020): 91–97. https://doi.org/10.1016/j.ahj.2020.08.001.

PMID
32871328
Full Text

Carnicelli, Anthony P., Sana M. Al-Khatib, Denis Xavier, Frederik Dalgaard, Peter D. Merrill, Daniel M. Wojdyla, Basil S. Lewis, et al. “Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.” Heart, September 16, 2020. https://doi.org/10.1136/heartjnl-2020-317229.

PMID
32938772
Full Text

Hijazi, Ziad, Christopher B. Granger, Stefan H. Hohnloser, Johan Westerbergh, Johan Lindbäck, John H. Alexander, Matyas Keltai, et al. “Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation.” J Am Heart Assoc 9, no. 18 (September 15, 2020): e017155. https://doi.org/10.1161/JAHA.120.017155.

PMID
32865097
Full Text

Hijazi, Ziad, Jonas Oldgren, Johan Lindbäck, John H. Alexander, Marco Alings, Raffaele De Caterina, John W. Eikelboom, et al. “Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.” Jama Netw Open 3, no. 9 (September 1, 2020): e2015943. https://doi.org/10.1001/jamanetworkopen.2020.15943.

PMID
32936298
Full Text

Jawitz, Oliver K., Tracy Y. Wang, Renato D. Lopes, Alma Chavez, Brittanny Boyer, Hwasoon Kim, Kevin J. Anstrom, et al. “Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.” Am Heart J 227 (September 2020): 91–99. https://doi.org/10.1016/j.ahj.2020.06.014.

PMID
32693197
Full Text

Pages